LOQUS23 THERAPEUTICS
About:
LoQus23 is a DDF-formed company focussing on targeting DNA damage repair pathways to treat Huntington’s disease.
Website: http://loqus23.com/
Top Investors: Forbion Capital Partners, SV Health Investors, Dementia Discovery Fund, Novartis Venture Fund
Description:
LoQus23 is a DDF-formed company focussing on targeting DNA damage repair pathways to treat Huntington’s disease and other triplet repeat diseases.
Total Funding Amount:
46.5M GBP
Estimated Revenue Range:
$1M to $10M
Headquarters Location:
London, England, United Kingdom
Founded Date:
2019-01-01
Founders:
David Reynolds
Number of Employees:
1-10
Last Funding Date:
2024-10-02
IPO Status:
Private
Industries:
© 2025 bioDAO.ai